Unknown

Dataset Information

0

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.


ABSTRACT: The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was undertaken at 4 occasions every day. Glucose values were used to assess several indices of glycemic control quality, such as glucose mean, GRADE, M-VALUE, hypoglycemia and hyperglycemia index, and indices of glycemic variability, such as standard deviation, CONGA, J-INDEX, and MAGE. We found that vildagliptin improved the glycemic condition compared to placebo: mean glycemic levels, and both GRADE and M-VALUE, were reduced by vildagliptin (P < 0.01). Indices also showed that vildagliptin reduced glycemia without increasing the risk for hypoglycemia. Almost all indices of glycemic variability showed an improvement of the glycemic condition with vildagliptin (P < 0.02), though more marked differences were shown by the more complex indices. In conclusion, the study shows that four-sample preprandial glucose self-monitoring is sufficient to yield information on the vildagliptin effects on glycemic control and variability.

SUBMITTER: Tura A 

PROVIDER: S-EPMC4637474 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.

Tura Andrea A   Farngren Johan J   Schweizer Anja A   Foley James E JE   Pacini Giovanni G   Ahrén Bo B  

International journal of endocrinology 20151026


The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was  ...[more]

Similar Datasets

| S-EPMC7921550 | biostudies-literature
| S-EPMC7806592 | biostudies-literature
| S-EPMC4025113 | biostudies-literature
| S-EPMC7467959 | biostudies-literature
| S-EPMC8079412 | biostudies-literature
| S-EPMC8173463 | biostudies-literature
| S-EPMC3781531 | biostudies-literature
| S-EPMC7005148 | biostudies-literature
| S-EPMC8474316 | biostudies-literature
| S-EPMC8173473 | biostudies-literature